California Institute of Technology

University of California

The Brigham and Women's Hospital, Inc.

Axial Therapeutics, Inc.

Washington University

City of Hope

Sarkis K Mazmanian

Paul H Patterson

Elaine Y Hsiao

Sara McBride

Timothy R Sampson

Antoinette Bailey

Dennis L Kasper

Olaf Schneewind

Gwen Liu

June L Round

Anthony Stewart Campbell

Michael A Fischbach

Hung Ton-That

Gil Sharon

Masanori Funabashi

Yue Shen

Janet Chow

Brittany D Needham

Sara Mcbride

Ryan Michael O'Connell

Edouard M Cantin

Herbert Virgin, Iv

Yunkyung Lee

Chandran Ramakrishna

Hiutung Chu

Sung-Eun Lee

Hong Ton-That

Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease.

Regulate gut microbiota to treat neurodegenerative disorders

Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include(e.g.,, and/or), and/or(e.g.,, or). Upon treatment, one or more ASD-related behaviors can be improved in the subject.

Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders

Provided is a method and a composition for improving behavioral performance in an individual comprising identifying an individual in need of treatment, and providing such an individual a composition comprising bacteria within the genus

Probiotic therapies for treating Rett syndrome

The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.

Inhibitors of microbially induced amyloid

Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

Modulation of microbial synthesis of 4-ethylphenol and 4-ethylphenyl sulfate in behavior and disease

Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut microbiota signature characteristic of an adult. The bacterial species can include(e.g.,, and/or), and/or(e.g.,, or). Upon treatment, one or more ASD-related behaviors can be improved in the subject.

Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

Immunomodulating compounds and related compositions and methods

PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases.

Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems

Provided herein are methods and systems and related compositions comprising an effective amount of one or more zwitterionic polysaccharide possibly in combination with one or more antibiotics, for treatment and/or prevention of sepsis or a condition associated thereto in an individual.

Sepsis treatment and related compositions methods and systems

Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease

Antigen specific regulatory T cells are described and related compositions, methods and systems. Methods to generate an antigen specific anti-inflammatory regulatory T cell is provided, the method comprising contacting either a T cell or an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen.

Antigen specific Tregs and related compositions, methods and systems

Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.

Growing community of inventors

Porter Ranch, CA, United States of America

Sarkis K Mazmanian